Illumina, Inc. (LON:0J8Z)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 24.17B +70.9% |
| Revenue (ttm) | 3.43B +5.9% |
| Net Income | 675.96M +27.3% |
| EPS | 4.34 +30.6% |
| Shares Out | n/a |
| PE Ratio | 36.80 |
| Forward PE | 36.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 328 |
| Open | 221.47 |
| Previous Close | 220.57 |
| Day's Range | 213.54 - 229.00 |
| 52-Week Range | 112.81 - 309.42 |
| Beta | 1.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
News
Illumina Transcript: UBS Global Healthcare Conference
Q3 momentum and strong clinical demand supported raised FY expectations, while the 2027 growth framework remains consumables-led. New products, pharma services and standardized multiomics datasets are positioned to add growth over time.
Illumina expands MRD portfolio with ultrasensitive duplex sequencing technology
Illumina (ILMN) announced an expansion of its molecular residual disease, or MRD, research portfolio with an early access program for an ultrasensitive sequencing workflow. Designed to detect trace am...
Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
Early access program launches to support ultrasensitive research into molecular residual disease and tumor evolution. New chemistry is optimized for highest possible accuracy, with reproducible detect...
Illumina price target lowered to $236 from $286 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Illumina (ILMN) to $236 from $286 and keeps a Neutral rating on the shares. The firm updated its model…
Illumina selected for whole-genome sequencing services in Singapore
The company states: “Illumina (ILMN) announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore’s National Precision Med...
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system S...
Illumina price target raised to $200 from $185 at Freedom Broker
Freedom Broker raised the firm’s price target on Illumina (ILMN) to $200 from $185 and keeps a Hold rating on the shares. Q3 beat expectations on consumables and margins, excluding…
Illumina price target raised to $210 from $113 at Citi
Citi analyst Patrick Donnelly raised the firm’s price target on Illumina (ILMN) to $210 from $113 and keeps a Sell rating on the shares.
Illumina price target lowered to $300 from $320 at JPMorgan
JPMorgan lowered the firm’s price target on Illumina (ILMN) to $300 from $320 and keeps an Overweight rating on the shares.
Illumina price target lowered to $275 from $290 at Evercore ISI
Evercore ISI lowered the firm’s price target on Illumina (ILMN) to $275 from $290 and keeps an Outperform rating on the shares.
Illumina price target raised to $300 from $225 at Stifel
Stifel raised the firm’s price target on Illumina (ILMN) to $300 from $225 and keeps a Buy rating on the shares.
Illumina Earnings Call Transcript: Q3 2026
Q3 revenue, margins and EPS beat guidance as clinical demand and NovaSeq X placements remained strong. FY26 revenue and EPS guidance rose; management sees high-single-digit consumables growth as the 2027 target and AI/data as longer-term opportunities.
Illumina Earnings release: Q3 2026
Illumina released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Illumina Slides: Q3 2026
Illumina has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Illumina Prepared remarks: Q3 2026
Illumina filed a regulatory document on October 29, 2026 disclosing important business information.
Illumina Quarterly report: Q3 2026
Illumina has published its Q3 2026 quarterly earnings report on October 29, 2026.
Illumina reports Q3 non-GAAP EPS $1.44, consensus $1.36
Reports Q3 revenue $1.13B, consensus $1.15B. “In Q3, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full…
Illumina raises FY26 EPS view to $5.40-$5.45 from $5.30-$5.40, consensus $5.36
Raises FY26 revenue view to $4.64B-$4.66B from $4.60B-$4.64B, consensus $4.62B.
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026. Third quarter 2026...
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conf...
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
Illumina downgraded to Equal Weight from Overweight at Stephens
Stephens downgraded Illumina (ILMN) to Equal Weight from Overweight with a price target of $275, up from $213.
Stephens downgrades Illumina and 10x Genomics following outperformance
As previously reported, Stephens analyst Mason Carrico downgraded Illumina (ILMN) to Equal Weight from Overweight with a price target of $275, up from $213, and 10x Genomics (TXG) to Equal…
Edwards Lifesciences added to ‘Core Ideas’ list at Evercore, Illumina removed
Evercore ISI raised the firm’s price target on Edwards Lifesciences (EW) to $102 from $100 and keeps an Outperform rating on the shares, which were also added to the firm’s…
Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery
DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and...